Lantern Pharma Inc. (LTRN) Key Metrics
LTRN valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $10.0M
- Enterprise value
- $10.4M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 9.7 10-yr median 1.4
- EV / EBITDA
- 0.2
- Dividend yield
- —
- Beta
- 2.32
LTRN key metrics, 2018–2025
Fiscal year ended December 31, 2025 · U.S. dollarsLTRN valuation Price multiples at each fiscal year-end price.
LTRN returns How much profit the business earns on the capital it uses.
LTRN per-share figures Results divided by the shares outstanding at year-end.
LTRN financial health Debt, liquidity and how easily interest is covered.
LTRN efficiency & capital use Working capital cycle and where the cash goes.
LTRN valuation history
LTRN returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
LTRN debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
LTRN cash returned to shareholders
LTRN price vs earnings per share
LTRN key metrics
2018–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Market capitalization | $33.0M | $34.3M | $46.4M | $65.5M | $87.0M | $119.8M | — | — |
| Enterprise value | $101.4M | $10.6M | $5.3M | $10.4M | $16.5M | $100.6M | — | — |
| Price / book | 5.1 | 1.6 | 1.1 | 1.2 | 1.2 | 6.1 | — | — |
| Earnings yield | −51.8% | −60.5% | −34.4% | −21,758.5% | −14.2% | −4.9% | — | — |
| Free cash flow yield | −47.5% | −51.9% | −31.0% | −19.5% | −12.2% | −4.7% | — | — |
| Shareholder yield (dividends + buybacks) | — | — | 1.1% | 3.8% | 1.1% | 0.0% | — | — |
| Share price at fiscal year-end | $3.03 | $3.19 | $4.28 | $6.04 | $7.98 | $19.25 | — | — |
| Per share | ||||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$1.57 | −$1.93 | −$1.47 | −$1,314.21 | −$1.13 | −$0.95 | −$0.39 | −$0.28 |
| Operating cash flow per share | −$1.44 | −$1.66 | −$1.32 | −$1.18 | −$0.97 | −$0.91 | −$0.34 | −$0.20 |
| Free cash flow per share | −$1.44 | −$1.66 | −$1.32 | −$1.18 | −$0.97 | −$0.91 | −$0.34 | −$0.20 |
| Cash per share | $0.93 | $2.23 | $3.81 | $5.09 | $6.49 | $3.09 | $0.20 | $0.07 |
| Book value per share | $0.60 | $1.97 | $3.77 | $5.16 | $6.56 | $3.17 | $0.15 | −$0.03 |
| Tangible book value per share | $0.60 | $1.97 | $3.77 | $5.16 | $6.56 | $3.17 | $0.15 | −$0.03 |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Debt per share | $7.21 | $0.02 | $0.02 | $0.00 | $0.02 | $0.02 | — | — |
| Shares outstanding | 10.9M | 10.8M | 10.8M | 10.9M | 10.9M | 6.2M | 6.3M | 6.2M |
| Change in shares outstanding | +1.3% | −0.7% | −0.1% | −0.5% | +75.3% | −0.7% | +0.8% | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | −123.5% | −66.9% | −32.9% | — | −27.1% | −57.2% | −655.0% | — |
| Return on invested capital (ROIC) | −39.2% | — | — | — | — | — | — | — |
| Return on assets (ROA) | −93.5% | −60.0% | −31.1% | — | −26.2% | −54.2% | −258.0% | −383.8% |
| Return on tangible assets | −155.1% | −81.3% | −36.6% | — | −16.7% | −29.0% | −169.5% | −383.8% |
| Financial health | ||||||||
| Total debt | $78.5M | $243,657 | $234,471 | $52,890 | $204,948 | $108,500 | — | — |
| Cash & short-term investments | $10.1M | $24.0M | $41.3M | $55.2M | $70.7M | $19.2M | $1.2M | $445,163 |
| Net debt | $68.4M | −$23.8M | −$41.1M | −$55.1M | −$70.5M | −$19.1M | −$1.2M | −$445,163 |
| Debt / equity | 12.02 | 0.01 | 0.01 | 0.00 | 0.00 | 0.01 | — | — |
| Debt / assets | 7.12 | 0.01 | 0.01 | 0.00 | 0.00 | 0.01 | — | — |
| Current ratio | 2.40 | 5.83 | 16.18 | 20.99 | 31.26 | 36.64 | 2.52 | 0.68 |
| Quick ratio | 2.40 | 5.83 | 16.18 | 21.20 | 31.34 | 36.64 | 2.52 | 0.68 |
| Interest coverage | — | — | — | — | -56.8 | — | — | — |
| Working capital | $6.3M | $20.9M | $40.7M | $55.9M | $70.4M | $19.7M | $743,526 | −$206,466 |
| Invested capital | $75.0M | −$2.6M | −$160,267 | $894,829 | $1.1M | $578,063 | −$288,746 | −$646,961 |
| Tangible asset value | $6.5M | $21.2M | $40.9M | $56.0M | $71.6M | $19.7M | $943,284 | −$201,798 |
| Net current asset value | $6.3M | $20.9M | $40.6M | $55.9M | $70.3M | $19.6M | $743,526 | −$206,466 |
| Graham net-net per share | $0.52 | $1.83 | $3.62 | $4.84 | $6.27 | $2.98 | $0.12 | −$0.03 |
| Capital allocation | ||||||||
| Share buybacks (net) | — | — | $499,997 | $2.5M | $939,666 | $0 | $0 | — |
| Capex / depreciation | 0.10 | 0.73 | 1.28 | 2.76 | 2.29 | 4.76 | 3.51 | — |
| Efficiency | ||||||||
| Days of inventory on hand | — | — | — | -912.0 | -678.1 | — | — | — |
| Days payables outstanding | 90,441.1 | 4,869.3 | 1,956.7 | 3,665.2 | 4,882.7 | 49,052.6 | 64,600.8 | -14,007.3 |
| Receivables turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| Payables turnover | 0.00 | 0.07 | 0.19 | 0.10 | 0.07 | 0.01 | 0.01 | −0.03 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $63,500 | $478,500 | $726,000 | $386,500 | $181,000 | — | — | — |
| Average payables | $4.3M | $2.5M | $937,309 | $1.6M | $1.3M | $455,316 | $287,960 | $97,629 |
| Average inventory | — | — | — | −$386,500 | −$181,000 | — | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from LTRN's annual financial statements (latest annual report filed March 30, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
LTRN valuation and financial ratios
Lantern Pharma earned a return on equity of −123.5% and a return on invested capital of −39.2% in fiscal 2025. It ended the year with $78.5 million of debt and $10.1 million in cash and short-term investments, net debt of $68.4 million. The share count rose 75.3% from 6.2M to 10.9M over 7 years.
See the LTRN income statement, the LTRN chart for price history, or the LTRN stock overview for the latest quote and news.
LTRN key metrics FAQ
What is Lantern Pharma's return on equity?
Lantern Pharma's return on equity (ROE) was −123.5% in fiscal 2025: net income of -$17.1 million on average shareholders' equity of $13.9 million.
What is Lantern Pharma's ROIC?
Lantern Pharma's return on invested capital was −39.2% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Lantern Pharma have?
Lantern Pharma had total debt of $78.5 million at the end of fiscal 2025, a debt-to-equity ratio of 12.02.
What is Lantern Pharma's free cash flow yield?
Lantern Pharma generated -$15.7 million of free cash flow in fiscal 2025, a free cash flow yield of −47.5% on its market value at year-end ($33.0 million).
What is Lantern Pharma's current ratio?
Lantern Pharma's current ratio was 2.40 at the end of fiscal 2025: current assets were 2.40 times current liabilities.